Diamond Biofund Statistics

Total Valuation

Diamond Biofund has a market cap or net worth of TWD 17.16 billion. The enterprise value is 12.66 billion.

Market Cap	17.16B
Enterprise Value	12.66B

Important Dates

The last earnings date was Friday, May 9, 2025.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

Diamond Biofund has 851.80 million shares outstanding. The number of shares has increased by 2.90% in one year.

Current Share Class	851.80M
Shares Outstanding	851.80M
Shares Change (YoY)	+2.90%
Shares Change (QoQ)	+0.52%
Owned by Insiders (%)	25.24%
Owned by Institutions (%)	5.10%
Float	179.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	-7.36
PB Ratio	1.83
P/TBV Ratio	1.83
P/FCF Ratio	5.71
P/OCF Ratio	5.70
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.88
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	4.21

Financial Position

The company has a current ratio of 66.73, with a Debt / Equity ratio of 0.01.

Current Ratio	66.73
Quick Ratio	66.69
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	0.04
Interest Coverage	-718.11

Financial Efficiency

Return on equity (ROE) is -24.34% and return on invested capital (ROIC) is -14.48%.

Return on Equity (ROE)	-24.34%
Return on Assets (ROA)	-14.42%
Return on Invested Capital (ROIC)	-14.48%
Return on Capital Employed (ROCE)	-26.40%
Revenue Per Employee	-70.67M
Profits Per Employee	-78.57M
Employee Count	33
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Diamond Biofund has paid 122.55 million in taxes.

Income Tax	122.55M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -46.05% in the last 52 weeks. The beta is 1.43, so Diamond Biofund's price volatility has been higher than the market average.

Beta (5Y)	1.43
52-Week Price Change	-46.05%
50-Day Moving Average	20.48
200-Day Moving Average	27.41
Relative Strength Index (RSI)	49.18
Average Volume (20 Days)	600,737

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Diamond Biofund had revenue of TWD -2.33 billion and -2.59 billion in losses. Loss per share was -3.04.

Revenue	-2.33B
Gross Profit	-2.33B
Operating Income	-2.49B
Pretax Income	-2.47B
Net Income	-2.59B
EBITDA	-2.49B
EBIT	-2.49B
Loss Per Share	-3.04

Full Income Statement

Balance Sheet

The company has 4.61 billion in cash and 105.97 million in debt, giving a net cash position of 4.50 billion or 5.28 per share.

Cash & Cash Equivalents	4.61B
Total Debt	105.97M
Net Cash	4.50B
Net Cash Per Share	5.28
Equity (Book Value)	9.37B
Book Value Per Share	10.95
Working Capital	4.55B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.01 billion and capital expenditures -1.81 million, giving a free cash flow of 3.01 billion.

Operating Cash Flow	3.01B
Capital Expenditures	-1.81M
Free Cash Flow	3.01B
FCF Per Share	3.53

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	106.98%
Pretax Margin	105.93%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Diamond Biofund does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.90%
Shareholder Yield	n/a
Earnings Yield	-15.11%
FCF Yield	17.52%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on August 7, 2023. It was a forward split with a ratio of 1.18.

Last Split Date	Aug 7, 2023
Split Type	Forward
Split Ratio	1.18

Scores

Diamond Biofund has an Altman Z-Score of 109.31 and a Piotroski F-Score of 2.

Altman Z-Score	109.31
Piotroski F-Score	2